During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on cereblon E3 ligase modulators (CELMoDs) for the treatment of non-Hodgkin lymphoma.
This discussion also featured Grzegorz Nowakowski, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný.
Prior to the discussion, Salles presented an overview of CELMoDs, highlighting their mechanism of action and introducing golcadomide as a novel agent under investigation for lymphomas. He reviewed emerging clinical data from early-phase trials evaluating golcadomide and iberdomide in relapsed/refractory non-Hodgkin lymphoma, including monotherapy and combinations with monoclonal antibodies. Additionally, he outlined the ongoing phase III GOLSEEK-1 and phase II GOLSEEK-2 trials investigating golcadomide in combination with rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) for high-risk large B-cell lymphoma and with rituximab for newly diagnosed advanced-stage follicular lymphoma, respectively.
This educational resource is independently supported by Bristol Myers Squibb. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.
